ΜΑΚΡΑΣ ΠΟΛΥΖΩΗΣ (2015)


 A Meta Analysis of Reference Markets of Bone Turnover for Prediction of Fracture
 A Model of BMD Changes After Alendronate Discontinuation to Guide Post Alendronte BMD Monitoring
 Bone specific insulin resistance disrupts whole body glucose homeostasis via decreased osteocalcin activation
 Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy
 Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism Summary Statement from the Fourth International Workshop
 Reassessment of Fracture Risk in women after 3 years of treatment with Zoledronic Acid when is it reasonable to discontinue treatment